Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
Aytu BioPharma (Nasdaq: AYTU) will report its fiscal 2026 first quarter operational and financial results after market close on Thursday, November 13, 2025. A conference call and webcast to review results and host Q&A is scheduled the same day at 4:30 p.m. Eastern time. Interested parties can join by phone using US dial-in (888) 506-0062 or international +1 (973) 528-0011 with participant access code 240426. The live webcast and archived replay will be available at the provided webcaster link and on Aytu’s Investors site under Events & Presentations. A teleconference replay is available through November 27, 2025 via replay numbers and access code 53111.
Aytu BioPharma (Nasdaq: AYTU) comunicherà i risultati operativi e finanziari del primo trimestre dell'esercizio 2026 dopo la chiusura del mercato giovedì 13 novembre 2025. Una conference call e una webcast per rivedere i risultati e ospitare una sessione di domande e risposte sono programmate nello stesso giorno alle 16:30 ora orientale. Le parti interessate possono partecipare telefonicamente chiamando dal numero US (888) 506-0062 o dall’estero +1 (973) 528-0011 con il codice di accesso partecipante 240426. La webcast in diretta e la replica archiviata saranno disponibili al link fornito dal webcaster e sul sito Investitori di Aytu sotto Events & Presentations. Una replay della teleconferenza è disponibile fino al 27 novembre 2025 tramite i numeri di replay e il codice di accesso 53111.
Aytu BioPharma (Nasdaq: AYTU) informará sus resultados operativos y financieros del primer trimestre fiscal de 2026 tras el cierre del mercado el jueves 13 de noviembre de 2025. Una llamada de conferencia y una transmisión web para revisar los resultados y moderar una sesión de preguntas y respuestas están programadas para ese mismo día a las 4:30 p.m. hora del Este. Las partes interesadas pueden unirse por teléfono llamando al US dial-in (888) 506-0062 o internacional +1 (973) 528-0011 con el código de acceso de participante 240426. La webcast en vivo y la reproducción archivada estarán disponibles en el enlace del webcaster proporcionado y en el sitio de Inversores de Aytu bajo Eventos y Presentaciones. Una reproducción de teleconferencia está disponible hasta el 27 de noviembre de 2025 mediante los números de reproducción y el código de acceso 53111.
Aytu BioPharma (Nasdaq: AYTU)은 2026 회계연도 1분기 운영 및 재무 실적을 2025년 11월 13일 목요일 장 마감 후 발표합니다. 같은 날 오후 4:30에 실적 검토 및 Q&A를 위한 컨퍼런스 콜과 웹캐스트가 예정되어 있습니다. 관심 있는 분들은 미국 다이얼인 번호 (888) 506-0062 또는 국제 전화 +1 (973) 528-0011으로 참여하고 참가자 접근 코드 240426를 입력하면 됩니다. 라이브 웹캐스트 및 보관용 재생은 제공된 웹캐스터 링크 및 Aytu의 투자자 사이트의 이벤트 및 발표 섹션에서 이용할 수 있습니다. 텔레컨퍼런스 재생은 2025년 11월 27일까지 재생 번호 및 접근 코드 53111로 이용 가능합니다.
Aytu BioPharma (Nasdaq: AYTU) publiera ses résultats opérationnels et financiers du premier trimestre fiscal 2026 après la clôture des marchés, le jeudi 13 novembre 2025. Une conférence téléphonique et une webcast pour examiner les résultats et organiser une session de questions-réponses sont prévues le même jour à 16h30, heure de l'Est. Les parties intéressées peuvent se joindre par téléphone en appelant le numéro US de dial-in (888) 506-0062 ou international +1 (973) 528-0011 avec le code d'accès participant 240426. Le webcast en direct et la rediffusion seront disponibles via le lien du webcaster fourni et sur le site des investisseurs d'Aytu sous Événements et Présentations. Une rediffusion de la téléconférence est disponible jusqu'au 27 novembre 2025 via les numéros de rediffusion et le code d'accès 53111.
Aytu BioPharma (Nasdaq: AYTU) wird im Geschäftsjahr 2026 die ersten Quartals-Operational- und Finanzzahlen nach Börsenschluss am Donnerstag, dem 13. November 2025, berichten. Eine Konferenzschaltung und ein Webcast zur Überprüfung der Ergebnisse und Beantwortung von Fragen sind am selben Tag um 16:30 Uhr Eastern Time geplant. Interessierte können sich telefonisch unter dem US-Dial-In (888) 506-0062 oder international +1 (973) 528-0011 mit dem Teilnehmenden-Zugangscode 240426 verbinden. Der Live-Webcast und die archivierte Wiedergabe stehen unter dem bereitgestellten Webcaster-Link und auf der Investoren-Website von Aytu unter Events & Presentations zur Verfügung. Eine Telekonferenz-Wiedergabe ist bis zum 27. November 2025 verfügbar, mit den Wiedergabe-Nummern und dem Zugangscode 53111.
Aytu BioPharma (بورصة ناسداك: AYTU) ستُعلن عن النتائج التشغيلية والمالية للربع الأول من السنة المالية 2026 بعد إغلاق السوق يوم الخميس 13 نوفمبر 2025. من المقرر عقد مؤتمر هاتفي وبث ويب لمراجعة النتائج واستضافة أسئلة وأجوبة في اليوم نفسه في الساعة 4:30 مساءً بتوقيت شرق الولايات المتحدة. يمكن للأطراف المهتمة الانضمام عبر الهاتف بالاتصال بالرقم الأميركي للمشاركة (888) 506-0062 أو دولياً +1 (973) 528-0011 مع رمز وصول للمشارك 240426. سيكون البث الحي عبر الويب والتشغيل المحفوظ متاحين عبر الرابط المقدم من الويب كاست وعلى موقع المستثمرين الخاص بـ Aytu ضمن قسم Events & Presentations. كما يتوفر إعادة تشغيل مؤتمر هاتفي حتى 27 نوفمبر 2025 عبر أرقام الإعادة ورمز الوصول 53111.
- None.
- None.
DENVER, CO / ACCESS Newswire / November 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025. The Company has scheduled a conference call and webcast that same day, Thursday, November 13, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.
Conference Call Details
Date and Time: Thursday, November 13, 2025, at 4:30 p.m. Eastern time.
Call-in Information: Interested parties can access the conference call by dialing (888) 506-0062 for United States callers or +1 (973) 528-0011 for international callers and using the participant access code 240426.
Webcast Information: The webcast will be accessible live and archived at https://www.webcaster5.com/Webcast/Page/2142/53111, and accessible on the Investors section of the Company's website at https://investors.aytubio.com/ under Events & Presentations.
Replay: A teleconference replay of the call will be available until November 27, 2025, at (877) 481-4010 for United States callers or +1 (919) 882-2331 for international callers and using replay access code 53111.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering our medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Aytu BioPharma (AYTU) report fiscal 2026 Q1 results?
What time is the Aytu (AYTU) earnings conference call on November 13, 2025?
How can investors join the AYTU November 13, 2025 webcast?
What are the phone numbers and access code to join the AYTU conference call?
Is there a replay for the Aytu (AYTU) November 13, 2025 call and how long is it available?
Where will Aytu (AYTU) post presentation materials for the November 13, 2025 results?
